Technical analysis of Chemomab Therapeutics Ltd. (CMMB): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24.
Price Performance
| 1 month | +38.74% |
| 3 months | +74.34% |
| Year-to-date | +60.61% |
| 1 year | +1.15% |
| 3 years | -36.30% |
52-Week Range
| 52-week High | $3.58 |
| 52-week Low | $1.35 |
| Avg Volume (90d) | 121K |
Technical Indicators
| SMA 50 | $2.01 |
| SMA 200 | $1.84 |
| Beta | 0.58 |
| 30-day Volatility (annualised) | 60.7% |
| Price vs SMA 50 | +31.6% |
| Price vs SMA 200 | +43.7% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $3.06 | |
| 2025-11 | $2.62 | -14.4% |
| 2025-12 | $1.65 | -37.0% |
| 2026-01 | $1.55 | -6.1% |
| 2026-02 | $1.86 | +20.0% |
| 2026-03 | $1.57 | -15.6% |
| 2026-04 | $1.47 | -6.4% |
| 2026-05 | $2.00 | +36.1% |
| 2026-06 | $1.62 | -19.0% |
| 2026-07 | $1.55 | -4.3% |
| 2026-08 | $2.72 | +75.5% |
| 2026-09 | $2.65 | -2.6% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-15 | | |
| 2026-09-15 | $-0.02 | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
| 2026-09-15 | | |
Price
| Price | $2.65 |
| Market Cap | $16M |
| Exchange | NASDAQ |
| Country | IL |
Valuation Ratios
| Price / Book | 2.44 |
| EV / EBITDA | -1.35 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 6.41 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -8.29 |